Some studies have suggested redundant roles for CCL2 and CCL4 (Mikucki et al., 2015) so we expected that our CCR2 and CCR5 armored CAR-T cells would be equivalent in terms of in vitro and in vivo tumor-directed homing and efficacy. This evidence concerns the gene CCL4 and neoplasm.